



Zelda Therapeutics Ltd
ACN 103 782 378
www.zeldatherapeutics.com
Level 45
108 St Georges Terrace,
Perth Western Australia 6000

25 November 2016

ZELDA EXPANDS INTELLECTUAL PROPERTY PORTFOLIO

HIGHLIGHTS

- **Zelda strengthens intellectual property portfolio, filing a series of international patent applications**
- **Working with one of Australia's leading patent attorney firms, medical cannabis IP landscape review reveals clear opportunity to build a strong portfolio backed by solid pre-clinical and clinical data**
- **Aligns with Zelda's strategy to build a diversified portfolio of valuable intellectual property**

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to announce that it has finalised the lodgement of a series of patent applications concerning certain aspects of its medical cannabis intellectual property across multiple medical indications.

The confirmation of lodgement follows a detailed intellectual property landscape review of the medicinal cannabis field conducted by highly regarded intellectual property law firm Griffith Hack (www.griffithhack.com). The review identified numerous areas where Zelda has the ability to secure an intellectual property position.

The lodgement of these patent applications provides a significant opportunity for Zelda to build a diversified portfolio of valuable intellectual property as it continues to invest in pre-clinical and clinical research and demonstrate solid data to underpin its patent claims.

Zelda will continue to focus on generating novel intellectual property which will be protected through a combination of patents and in-house know-how. In addition, it is pursuing discussions with groups holding complementary technologies that may have benefit to Zelda either as jointly owned or licensed intellectual property.

Executive Chairman Harry Karelis stated: *"Our investment in building a solid portfolio of intellectual property is a core part of Zelda's business model. We believe that in time, as the global medicinal cannabis sector continues to expand, that those companies holding proprietary intellectual property positions along with well respected brands, will attract premium valuations. Investors can expect to see Zelda continue to invest in this area."*

CONTACTS

Corporate

Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Media

Andrew Ramadge
Media & Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda's*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols. Zelda will use this information to design a series of human clinical trials that have a high probability of success given the existing patient data and experiences it has access to.

In addition, Zelda has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry.